PCSK9 and cardiovascular disorder: This suggests that interventions such as siRNA (59), anti-sense RNA, ribozymes, or gene editing, that are targeted at PCSK9 gene expression in the liver might benefit cardiovascular disease even more than can be achieved by administration of PCSK9 monoclonal antibodies.